{"id":401101,"date":"2025-11-24T10:17:16","date_gmt":"2025-11-24T10:17:16","guid":{"rendered":"https:\/\/www.europesays.com\/us\/401101\/"},"modified":"2025-11-24T10:17:16","modified_gmt":"2025-11-24T10:17:16","slug":"ozempic-users-win-eye-disease-payout-in-novos-home-market","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/401101\/","title":{"rendered":"Ozempic Users Win Eye-Disease Payout in Novo\u2019s Home Market"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody__3UcBa\" data-component=\"paragraph\">Four patients who developed a serious eye disease after using Novo Nordisk A\/S\u2019s blockbuster weight-loss drugs have been granted compensation in Denmark, the drugmaker\u2019s home market.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody__3UcBa\" data-component=\"paragraph\">The claimants received a combined 800,000 kroner ($124,000), though that figure may rise if further loss of earnings is proven, <a href=\"https:\/\/patienterstatningen.dk\/presse-og-nyheder\/nyheder\/2025\/nov\/de-foerste-patienter-faar-erstatning-for-alvorlig-oejensygdom-efter-wegovy-og-ozempic\" title=\"statement\" target=\"_blank\" rel=\"noopener\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">according<\/a> to Danish Patient Compensation, an independent association financed by the state and insurers. <\/p>\n","protected":false},"excerpt":{"rendered":"Four patients who developed a serious eye disease after using Novo Nordisk A\/S\u2019s blockbuster weight-loss drugs have been&hellip;\n","protected":false},"author":3,"featured_media":401102,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[29062,1230,13656,189904,525,454,141618,14232,210,62224,1060,62221,3229,67,132,68],"class_list":{"0":"post-401101","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-denmark","9":"tag-drugs","10":"tag-earnings","11":"tag-european-medicines-agency","12":"tag-finance","13":"tag-government","14":"tag-great-britain","15":"tag-harvard-university","16":"tag-health","17":"tag-industries","18":"tag-medication","19":"tag-novo-nordisk-a-s-b","20":"tag-regulation","21":"tag-united-states","22":"tag-unitedstates","23":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115604163612384235","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/401101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=401101"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/401101\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/401102"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=401101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=401101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=401101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}